BPC-157 TB-500 dosage, as studied — not as prescribed

BPC-157 and TB-500 Dose Ranges in Preclinical Studies

BPC-157 TB-500 dosage has no validated value for the blend. The figures below come from single-compound animal studies and describe what was administered to which species by which route — they are not human guidance and do not translate to a blend dose. The framing throughout this page is deliberate: "studied at X in [species] by [route]," never "take X."

The BPC-157 component, in rodent models, is commonly expressed per body weight, frequently around 10 microg/kg and 10 ng/kg; gastric-ulcer cytoprotection was studied at 400-800 ng/kg in rats ^[1]. Expressing a dose per kilogram of body weight is how animal pharmacology works, and it is precisely why those numbers cannot be lifted into a fixed human milligram amount. The TB-500 / Thymosin Beta-4 component spans a far wider range: 2-18 mg/kg intraperitoneal in a rat embolic-stroke dose-response study (modeled optimum ~3.75 mg/kg, while 18 mg/kg gave no benefit — higher was not better), and 150 microg twice weekly intraperitoneally for six months in the mdx muscular-dystrophy study ^[4]. That non-monotonic result — a high dose performing worse than a middle one — is the single most useful caution on this page, because it directly contradicts the loading logic behind many community blend protocols.

Human single-agent reference points exist only for full-length Thymosin Beta-4, not the blend: intravenous Thymosin Beta-4 was well tolerated in Phase 1 work ^[4]. Commercial vials commonly pair fixed combined masses (e.g. ~10 mg + ~10 mg), but no peer-reviewed combination dose-finding study exists, and the fixed-mass label is a packaging convention, not a validated dose ^[1].

Per-Day Framing: Why No Validated Daily Blend Dose Exists

A per-day blend dose cannot be stated because no controlled trial has defined one. Commercial fixed-mass vials (e.g. 10 mg + 10 mg) have no controlled-trial basis for a daily blend dose, and the underlying rodent studies expressed dosing per body weight on study-specific schedules, not as a human daily amount ^[1][4]. Treat any "per day" figure circulating for the blend as unvalidated.

How Much BPC-157 and TB-500 Is Used Per Week in Studies?

There is no validated weekly dose for the blend. Animal studies express BPC-157 per body weight (often ~10 microg/kg or ~10 ng/kg) and used TB-500 / Thymosin Beta-4 across a wide range — for example 150 microg twice weekly intraperitoneally in one six-month mouse study ^[1][4]. None of it translates to a human weekly blend dose.

Routes, Half-Life, and Handling in the Research

The routes the research used are not the routes the community uses, and the distinction matters for anyone reading vendor protocols. The underlying rodent efficacy studies for both peptides were predominantly intraperitoneal; human Phase 1 data for full-length Thymosin Beta-4 and a BPC-157 safety pilot used intravenous routes ^[1][4]. Subcutaneous and intramuscular administration are the predominant research-community routes for the blend, but they do not come from controlled human efficacy trials.

Half-Life of BPC-157 and TB-500

No validated human pharmacokinetic half-life exists for either constituent at research doses, and none for the blend. BPC-157 elimination half-life was under 30 minutes in a rat/dog study; human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life rising at higher doses, but no specific half-life is established for the TB-500 heptapeptide ^[4].

Oral vs. Injected Routes in the Research

BPC-157 is studied as a stable gastric peptide, so oral routes appear in its individual-compound literature ^[1]. Blend oral products are marketed but lack validated pharmacokinetics. The rodent efficacy studies for both peptides were predominantly injected (intraperitoneal), so oral blend bioavailability is not established by controlled data.

Oral vs. Injection: Bioavailability Considerations

Bioavailability favors injection in the published data. BPC-157's elimination half-life was under 30 minutes in animal pharmacokinetics, and its intramuscular bioavailability in animals was modest ^[1][4]. No controlled human study characterizes oral or injected bioavailability for the blend, so route comparisons for "Wolverine" products are inferences, not measured values.

Reconstituting a BPC-157 / TB-500 Blend

Both constituents are supplied as lyophilized powders, reconstituted in bacteriostatic or sterile water and refrigerated; a common community practice is to reconstitute the two separately or in a shared vial ^[1]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed — see reconstitution and injection practice.

Reconstitution and Injection Practice in Research Settings

Lyophilized powder is dissolved in a sterile diluent for handling; the predominant research-community routes are subcutaneous and intramuscular, while the underlying rodent efficacy studies used intraperitoneal dosing ^[1][4]. These practices are not drawn from controlled human efficacy trials. Identity and ratio of unregulated "Wolverine" material remain unverified outside formal studies.

Injection Frequency in the Research

No validated blend frequency exists. The underlying rodent studies used predominantly intraperitoneal dosing on study-specific schedules — for example one six-month mouse Thymosin Beta-4 study used 150 microg twice weekly ^[4]. Community "loading then maintenance" blend protocols have no controlled-trial basis.

Cycling BPC-157 and TB-500

No validated cycle exists. Community "loading then maintenance" schedules and fixed-ratio vials (e.g. 10 mg + 10 mg) have no basis in controlled human trials and should not be presented as validated dosing. Mixed and non-monotonic preclinical results — 18 mg/kg Thymosin Beta-4 gave no benefit in one rat study — undercut "more is better" loading rationales ^[4].